Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Luye Pharma Group ( (HK:2186) ) has provided an update.
Luye Pharma Group reported solid top- and bottom-line growth for 2025, with revenue rising 4.1% year-on-year to RMB6.31 billion and gross profit increasing 2.9% to RMB4.16 billion, yielding a gross margin of 66.0%. The company’s earnings strength was reflected in a 12.7% gain in EBITDA to RMB2.47 billion and a 26.6% jump in basic earnings per share to RMB0.1588.
Profit before tax climbed 12.6% to RMB944.6 million, while net profit advanced to RMB705.7 million, supported by higher other income despite increased administrative and finance costs and a loss from associates. Profit attributable to shareholders rose to RMB618.7 million, but the board opted not to propose a dividend for 2025, signaling a potential focus on reinvestment or balance sheet priorities that may influence shareholder return expectations.
The most recent analyst rating on (HK:2186) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group Ltd. is a Hong Kong-listed pharmaceutical company incorporated in Bermuda, focused on the research, development, manufacturing and commercialization of prescription drugs. The group primarily generates revenue from branded specialty medicines, with a portfolio that supports its position in key therapeutic areas in China and selected international markets.
Average Trading Volume: 15,642,867
Technical Sentiment Signal: Sell
Current Market Cap: HK$9.47B
For detailed information about 2186 stock, go to TipRanks’ Stock Analysis page.